| Original language | English |
|---|---|
| Journal | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging |
| Early online date | 9 Sept 2022 |
| DOIs |
|
| Publication status | E-pub ahead of print - 9 Sept 2022 |
Access to Document
- 10.1016/j.bpsc.2022.09.002Licence: Unspecified
- Natural language processing_PATEL_Publishedonline9September2022_GREEN AAMAccepted author manuscript, 179 KBLicence: CC BY-NC-ND
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 09.09.2022.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Natural language processing: unlocking the potential of electronic health record data to support transdiagnostic psychiatric research
AU - Patel, Rashmi
AU - Wickersham, Matthew
AU - Cardinal, Rudolf N.
AU - Fusar-Poli, Paolo
AU - Correll, Christoph U.
N1 - Funding Information: RP has received grant funding from Janssen and personal fees from Holmusk. RNC consults for Campden Instruments Ltd. and receives royalties from Cambridge University Press, Cambridge Enterprise, and Routledge. PF-P has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Mindstrong, and Proxymm Science, outside the current study. CUC has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. CUC provided expert testimony for Janssen and Otsuka and served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. CUC has received grant support from Janssen and Takeda, has received royalties from UpToDate, and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic. MW reports no biomedical financial interests or potential conflicts of interest. Funding Information: RP has received funding from National Institute for Health Research (NIHR) Advanced Fellowship Grant No. NIHR301690 and Medical Research Council (MRC) Health Data Research UK Fellowship Grant No. MR/S003118/1 . RNC is supported by MRC Grant No. MR/W014386/1 . All research at the Department of Psychiatry in the University of Cambridge is supported by UK National Health Service NIHR Cambridge Biomedical Research Centre Grant No. BRC-1215-20014 and the NIHR East of England Applied Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
PY - 2022/9/9
Y1 - 2022/9/9
UR - http://www.scopus.com/inward/record.url?scp=85143517385&partnerID=8YFLogxK
U2 - 10.1016/j.bpsc.2022.09.002
DO - 10.1016/j.bpsc.2022.09.002
M3 - Comment/debate
SN - 2451-9022
JO - Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
JF - Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
ER -